Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.

Clinical Therapeutics
Elizabeth M ShermanJason J Schafer

Abstract

This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy and tolerability, drug interactions, and dosing and administration of cobicistat. Searches of MEDLINE and International Pharmaceutical Abstracts from 1964 to February 2015 were conducted using the search terms cobicistat and GS-9350. Relevant information was extracted from the identified clinical trials and review articles. Abstracts from the Conference on Retroviruses and Opportunistic Infections (2014-2015) and the Interscience Conference on Antimicrobial Agents and Chemotherapy (2013-2014) were also searched. Cobicistat is a PK enhancer lacking antiviral activity that, via selective cytochrome P-450 (CYP) 3A inhibition, inhibits the metabolism of certain antiretroviral medications and is used for prolonging their effect. Cobicistat has been studied as a booster of elvitegravir, a second-generation integrase inhibitor, and of the protease inhibitors atazanavir and darunavir. Data on its clinical efficacy and tolerability have been presented in 2 Phase II trials and in 9 Phase III trials, which reported durable efficacy in terms of achievement of sustained suppression of HIV-1 RNA levels to <50 copies/mL for a...Continue Reading

References

Jul 7, 2007·Critical Reviews in Toxicology·Yasuhiro Masubuchi, Toshiharu Horie
Jan 1, 2010·Clinical Pharmacology and Therapeutics·A A MathiasB P Kearney
Jun 27, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Polina GermanAnita Mathias
Jun 19, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Srinivasan RamanathanBrian P Kearney
Feb 20, 2014·Antimicrobial Agents and Chemotherapy·Joseph M CustodioSrinivasan Ramanathan
Aug 12, 2010·ACS Medicinal Chemistry Letters·Lianhong XuManoj C Desai
Jul 16, 2014·Antimicrobial Agents and Chemotherapy·William WeissRichard Vickers
Dec 1, 2014·HIV Clinical Trials·Cheryl K McDonaldJavier Szwarcberg

❮ Previous
Next ❯

Citations

Nov 1, 2016·Expert Opinion on Pharmacotherapy·Nathan R UngerLindsey M Childs-Kean
Jun 2, 2017·Cell Death & Disease·Mayilaadumveettil NishanaSathees C Raghavan
May 31, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Mohamed G AttaGregory M Lucas
Sep 2, 2017·The Journal of Pharmacology and Experimental Therapeutics·Rachel A Murphy, Monica A Valentovic
Nov 2, 2019·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoGiuliano Rizzardini
Feb 26, 2016·AIDS·Stein SchalkwijkUNKNOWN PANNA network
Oct 14, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul E SaxJohn R Koethe
Jan 9, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Dario Cattaneo, Cristina Gervasoni
Oct 29, 2020·Archives of Toxicology·Jukka HakkolaOlavi Pelkonen
Feb 12, 2021·AIDS Research and Human Retroviruses·Lawrence D YorkLori E Fantry
Feb 24, 2021·AIDS Research and Human Retroviruses·Jovana MilicGiovanni Guaraldi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.